Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-244-4990
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.62 million
Profitability
Miscellaneous
Employees23
Next Earnings Date4/6/2020 (Estimated)
OptionableOptionable
Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions
What is Titan Pharmaceuticals' stock symbol?
Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."
When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?
Titan Pharmaceuticals shares reverse split on Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.
How were Titan Pharmaceuticals' earnings last quarter?
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings results on Thursday, November, 14th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. The specialty pharmaceutical company earned $0.95 million during the quarter, compared to the consensus estimate of $1 million. Titan Pharmaceuticals had a negative return on equity of 962.95% and a negative net margin of 441.23%. View Titan Pharmaceuticals' Earnings History.
When is Titan Pharmaceuticals' next earnings date?
What price target have analysts set for TTNP?
1 equities research analysts have issued 12-month target prices for Titan Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.00. On average, they expect Titan Pharmaceuticals' stock price to reach $1.00 in the next year. This suggests a possible upside of 199.4% from the stock's current price. View Analyst Price Targets for Titan Pharmaceuticals.
What is the consensus analysts' recommendation for Titan Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Titan Pharmaceuticals.
Has Titan Pharmaceuticals been receiving favorable news coverage?
Media headlines about TTNP stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Titan Pharmaceuticals earned a news impact score of -1.5 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Titan Pharmaceuticals.
Who are some of Titan Pharmaceuticals' key competitors?
Some companies that are related to Titan Pharmaceuticals include Neon Therapeutics (NTGN), Vical (VICL), BioCardia (BCDA), Entera Bio (ENTX), Outlook Therapeutics (OTLK), aTyr Pharma (LIFE), CytRx (CYTR), Vaxart (VXRT), Genetic Technologies (GENE), Aevi Genomic Medicine (GNMX), TRACON Pharmaceuticals (TCON), TrovaGene (TROV), Enzon Pharmaceuticals (ENZN), AIM ImmunoTech (AIM) and Seneca Biopharma (SNCA).
What other stocks do shareholders of Titan Pharmaceuticals own?
Who are Titan Pharmaceuticals' key executives?
Titan Pharmaceuticals' management team includes the folowing people:
- Dr. Marc Rubin, Exec. Chairman (Age 64)
- Mr. Sunil Bhonsle, Pres, CEO, Principal Financial Officer & Director (Age 69)
- Dr. Katherine L. Beebe-DeVarney Ph.D., Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer (Age 50)
How do I buy shares of Titan Pharmaceuticals?
Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Titan Pharmaceuticals' stock price today?
One share of TTNP stock can currently be purchased for approximately $0.33.
How big of a company is Titan Pharmaceuticals?
Titan Pharmaceuticals has a market capitalization of $18.55 million and generates $6.62 million in revenue each year. The specialty pharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Titan Pharmaceuticals employs 23 workers across the globe.View Additional Information About Titan Pharmaceuticals.
What is Titan Pharmaceuticals' official website?
How can I contact Titan Pharmaceuticals?
Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]
MarketBeat Community Rating for Titan Pharmaceuticals (NASDAQ TTNP)
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
